BRITTANY ABSHIRE: Open Payments
NPI 1730619099 · STAUNTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,690 in 97 payments from 10 companies in 2025. Trend: 2023 $870 · 2024 $1,830 · 2025 $1,690
Food & beverage: $1,690
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 37 | $426 |
| Janssen Pharmaceuticals, Inc | 18 | $384 |
| Teva Pharmaceuticals USA, Inc. | 14 | $296 |
| Otsuka America Pharmaceutical, Inc. | 10 | $262 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| ABBVIE INC. | 4 | $76 |
| E.R. Squibb & Sons, L.L.C. | 4 | $69 |
| Lundbeck LLC | 3 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Alkermes, Inc. | 1 | $18 |
Products named: INGREZZA, SPRAVATO, INVEGA SUSTENNA, UZEDY, REXULTI, ABILIFY MAINTENA, AUSTEDO XR, CAPLYTA.
Industry payments across VA — which companies pay providers there.
